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Summary 
Diabetes is the most frequently encountered endocrine disorder in pregnancy and is 
associated with adverse outcomes. Despite the urgent need for interventions to 
improve the outcomes for pregnancies complicated with diabetes, and the consistent 
recognition of preconception care as an effective intervention, there has been lack of 
systematically produced evidence to support it.  
My first publication (Preconception Care for Diabetic Women for Improving 
Maternal and Fetal Outcomes: a Systematic Review and Meta-analysis) was the first 
systematically produced high level evidence addressing the effectiveness and the 
safety of all aspects of preconception care. This publication had high impact on 
practice and research evident by the incorporation of its findings in clinical guidelines 
and the number of times it was cited in the literature. My second publication (Pre-
pregnancy care for women with pre-gestational diabetes mellitus: a systematic review 
and meta-analysis) was designed for deeper analysis of the safety of preconception 
care.  
The third and the fourth publications addressed the prevalence of pre-gestational and 
gestational diabetes and the rate of complications associated with diabetes in 
pregnancy in Saudi Arabia and contributed to the quantification of diabetes in 
pregnancy as a public health problem in the country. These two publications provided 
important information, considering that there was paucity of publications about 
diabetes in pregnancy in Saudi Arabia for more than a decade, and they gave the 
needed evidence to revise the hospital policy for screening and management of 
diabetes in pregnancy as well as the implementation of preconception care for women 
with pre-existing diabetes.  
My fifth publication investigated an important clinical intervention for pregnant 
women with diabetes which is induction of labour. Similar to the second and third 
publication there was paucity of information about the indications and the 
determinants of successful induction of labour in Saudi Arabia. This publication was 
the first to address this important intervention in the practice of obstetrics in general 
and in the specific management of women with diabetes.  
Thus my work in “diabetes in pregnancy as a clinical and public health problem” 
provided an important evaluation of interventions at the clinical and public health 
levels and important information for the management of diabetic pregnant women in 
Saudi Arabia and across the world.  
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Background: 
Epidemiology of pre-gestational and gestational diabetes mellitus worldwide: 
Diabetes mellitus (DM) is a global public health problem with expected 300 million 
diabetics by the year 2030 worldwide [1]. In many areas around the globe including 
the West as well as many developing and Middle Eastern countries, diabetes has 
become a major health burden affecting young adults and women in their 
reproductive age [2,3]. As the burden of the disease increases the management of 
pregnancies complicated by DM will be part of the daily obstetric practice in many 
regions of the world.  
Pregnancies complicated with pre-gestational diabetes mellitus (pre-GDM) are 
associated with a high rate of complications compared to the background population; 
including increased perinatal mortality and congenital malformations [4,5]. A recent 
systematic review showed that pregnancies complicated by type 2 diabetes mellitus 
(T2DM) are associated with worse perinatal and neonatal mortality than those 
complicated by type 1 diabetes mellitus (T1DM) [6]. Studies investigating the 
influence of ethnicity on the outcome of pregnancies complicated by pre-GDM 
reported variation in the outcome with different ethnic groups with worse outcome for 
Asian [7] and Afro-Caribbean mothers compared to Caucasian [8], however this 
difference might be explained by access to and utilization of preconception and 
prenatal care [8]. 
Gestational diabetes mellitus (GDM) “is carbohydrate intolerance that begins or is 
first recognized during pregnancy” [9]. There is great variation in the prevalence of 
GDM among different ethnic groups and communities; it ranges from less than 2% to 
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22% [10]. Epidemiological studies confirmed that the prevalence of GDM is in direct 
proportion to the prevalence of T2DM [11], in addition women who developed GDM 
are at increased risk of developing T2DM [12,13]. Obesity, high weight gain during 
pregnancy, increased parity and advanced maternal age are recognized risk factors for 
developing GDM [11,14,15]. Similar to pre-GDM, GDM is associated with 
considerable maternal, fetal and neonatal complications [16,17]. In addition, recent 
reports confirmed that GDM has long term effects on the mothers and their children 
including increase risk of developing T2DM, maternal and childhood obesity and 
cardiovascular disease [18]. 
Epidemiology of pre-GDM and GDM in Saudi Arabia: 
Recent population based studies in Saudi Arabia estimated the prevalence of T2DM 
to be between 21% to 24% [19], which reflects a fivefold increase in the affected 
population in just over 20 years [20]. Among the Middle East countries, the Gulf 
region countries showed the highest prevalence of DM; with the Kingdom of Saudi 
Arabia (KSA) reported the highest prevalence compared to the other Gulf countries. 
The rapidly increasing prevalence of T2DM has been attributed to the fast changes in 
lifestyle, dietary habits, and physical activity of the Saudi community associated with 
the socio-economic  changes and fast urbanization [21]. The World Health 
Organization predicted that DM prevalence in KSA will increase by 183% over the 
20 years following 2003 [22].   
Despite the confirmed high prevalence of DM, only few studies addressed the 
prevalence and the effect of maternal diabetes on pregnancy outcomes in KSA.  
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Similar to other parts of the world diabetes in pregnancy in KSA is associated with 
increased maternal age, parity and body mass index [23-25]. Although most of these 
studies were hospital based, yet they showed that almost one fourth of the women 
admitted for delivery in one hospital had either GDM or pre-GDM [26,27] with 
demonstrable adverse pregnancy outcomes when compared to non-diabetic women 
[26,27], including higher rate of macrosomia, cesarean section delivery (C/S), 
preterm delivery, perinatal mortality and birth injuries [26-29]. In addition newborns 
of diabetic mothers had higher rate of admission to intensive care unit and higher rate 
of metabolic disorders [30]     
The reported  prevalence of GDM, from the different hospital based studies, ranges 
between 5-18%, depending on different diagnostic criteria, and that of pre-GDM is 
3.7-4.2% [27,28], yet the overall incidence and prevalence of GMD and pre-GDM, or 
economic burden of these important conditions on the health service provision in 
KSA, is not known due to lack of population based studies in this area, which reflects 
negatively on the estimation of impact of any preventive or health promotional 
programs directed towards reducing the burden of GDM and pre-GDM. 
The importance of the published literature as source of information for the policy 
makers cannot be stressed more keeping in mind that there is no national database for 
maternity health problems in KSA. There is scarcity of information about the 
standard of health services provided to diabetic pregnant women in addition to lack of 
national guidelines for screening and treatment of diabetes during pregnancy.  
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Fetal, neonatal and maternal complications of diabetes in pregnancy: 
The physiological changes of pregnancy cause a state of carbohydrate intolerance. 
Pregnancy specific hormones such as human placental lactogen and the increased 
levels of cortisol and prolactin, increase insulin resistance and call for more 
production of insulin  to maintain normal blood glucose level during pregnancy [31]. 
Such demand is not met in pregnant diabetic women due to the pathology associated 
with diabetes. 
The hyperglycemia in T2DM is due to decreased uptake of glucose by the peripheral 
tissue together with increased hepatic production, this is secondary to reduced 
production of insulin from the pancreatic β cells and to increased peripheral resistance 
to insulin [32,33]. On the other hand the hyperglycemia in T1DM is caused by 
complete destruction of the β cells of the pancreas due to the interplay of auto-
immune, genetic and environmental factors [34-36]. 
The hyperglycemia in GDM typically appears late in pregnancy, hence the 
recommended screening time between 24-28 gestation weeks.  
Maternal hyperglycemia stimulates fetal hyperinsulinemia with subsequent increase 
and abnormal fat distribution on the fetus [37]. Recent studies have confirmed that 
hyperglycemia at levels even lower than that for DM in non-pregnant subjects, is 
associated with adverse pregnancy outcomes in a linear relationship [38]. 
The effect of hyperglycemia on the pregnancy outcomes varies with the level of 
maternal blood glucose and the time during pregnancy with uncontrolled 
hyperglycemia. Hyperglycemia occurring early in pregnancy and during 
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organogenesis, as in the case of uncontrolled T1DM and T2DM, is associated with 
risk of congenital malformations, macrosomia, stillbirth, birth asphyxia and preterm 
delivery, while the same complications might appear with GDM but less frequent and 
less severe due to the late occurrence of the hyperglycemia [17,39].  
The teratogenicity of pre-GDM has long being recognized [40]. Observational studies 
indicated an increased risk of congenital abnormalities in pregnancies complicated by 
GDM [40]; however this observation might be due to the inclusion of women with 
unrecognized T2DM in the study population.  
Uncontrolled maternal hyperglycemia adversely influences fetal weight and growth 
with resultant macrosomia at moderately elevated levels and intra-uterine growth 
restriction at very high levels of maternal blood glucose [41]. Macrosomia is 
associated with significant maternal and perinatal complications including increased 
rate of C/S, birth asphyxia and perinatal mortality [42].   
A recent report confirmed that the rate of both iatrogenic and spontaneous preterm 
deliveries are increased in mothers who are diabetic compared to the background 
population [43] nevertheless, premature infants of diabetic mothers do not seem to be 
at risk of complications more than the preterm infants of non-diabetic mothers [44]. 
The reason behind the tendency towards delivery by C/S is in great part attributed to 
the increased rate of macrosomia among women with pre-GDM and GDM, however 
significant association was found between the risk of C/S delivery in diabetic women 
and maternal obesity, uncontrolled diabetes and unplanned pregnancy [45]. Recent 
reports found that with the increase rate of elective C/S there was improvement in the 
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rate of shoulder dystocia and its associated morbidities [46] as well as of APGAR 
scores at 5 minutes [47], nevertheless the effectiveness and cost effectiveness of the 
approach of screening for macrosomia by ultrasound scanning, fetal weight 
estimation and subsequent delivery by elective C/S was doubted by other 
investigators [48]. 
The stillbirth rate among women with pre-GDM is high compared to the background 
population.  Recent review on the causes of perinatal mortality in women with pre-
GDM showed that antepartum asphyxia and congenital abnormalities were the 
leading two causes of stillbirth [41]. Placental angiopathy secondary to uncontrolled 
maternal hyperglycemia was suggested as an etiology for antenatal asphyxia [41] and 
peri-conception uncontrolled hyperglycemia as the cause of congenital abnormalities 
[49].  
Prevention and treatment of complications of pre-GDM and GDM: 
Despite improved access and quality of antenatal care, women with pre-GDM and 
their fetuses are at increased risk of developing serious complications compared with 
the non-diabetic pregnant women [50,51].  
Evidence for effectiveness and safety preconception care for women with pre-
GDM:  
Pre- GDM and the associated maternal hyperglycemia during the time of 
organogenesis is a known teratogen with detrimental effects on the fetal heart, renal, 
musculoskeletal and central nervous systems [50,52,53]. Population based studies 
showed that there is a fivefold increase in the rate of cardiovascular malformations, 
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and more than twofold increase in the rate of neural tube defects and urinary tract 
abnormalities in infants of diabetic mothers when compared to the background 
population [52,53]. Moreover congenital malformations are associated with increased 
risk of stillbirth and perinatal mortality as they account for almost 50% of all deaths 
of infants born to mothers with pre-GDM [54,55] . Congenital malformations 
secondary to maternal diabetes can be prevented, in great part, by optimizing 
maternal health in the preconception period. Glycemic control is one of the most 
important aspects of preconception care (PCC) [56]; however other aspects of care 
such as folic acid supplementation, smoking cessation, screening and treatment of 
diabetes complications and discontinuing teratogenic medications, are as important 
for improving maternal and fetal outcomes and might be effective in reducing the rate 
of congenital malformations to the background level [49,57,58]. The evidence for the 
effectiveness of PCC for women with pre-GDM, in the form of optimization of blood 
glucose level, folic acid supplementation, detection and treatment of retinopathy and 
modification of medication has been consistent since 1982 [59]. However previous 
studies that addressed PCC are either outdated and limited to selected outcomes of 
pregnancy [56] or to one center of care [33], which created an urgent need for high 
level of evidence for this important intervention.     
Screening for pre-GDM and GDM: 
There were controversies about screening and treatment of GDM [60] as well as 
about early diagnosis of T2DM in pregnancy, however recent reports proved the 
importance of universal screening and treatment in communities with high prevalence 
of GDM and T2DM [61,62]. Following the analysis of the results of the study 
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hyperglycemia and adverse pregnancy outcome (HAPO) [38], a consensus about 
diagnosis and screening of hyperglycemia in pregnancy was reached by 
representatives of 10 international organizations; the International Association of 
Diabetes and Pregnancy Study Group (IADPSG) and the recommendations included 
the use of 2 hours 75g oral glucose tolerance test (OGTT) for all pregnant women 
between 24 and 28 week of pregnancy to screen and diagnose GDM. The criteria for 
diagnosing GDM is based on one or more abnormal value of the following; fasting 
blood glucose ≥ 5.1 mmol/l, 1 hour ≥10 mmol/l and 2 hours ≥ 8.5 mmol/l [63]. The 
group also recommended early screening of all pregnant women for T2DM during the 
first antenatal visit using either fasting blood glucose with a cut-off level ≥7.0 mmol/l 
or glycosylated hemoglobin A (HbA1c) of ≥ 6.5% [63]. The advantage of the 
recommendation of the IADPSG over previously suggested criteria for the diagnosis 
of GDM is that they are linked to the risk of adverse pregnancy outcomes rather than 
to the diagnosis of diabetes outside pregnancy. Moreover, the recommendations 
addressed the issue of undiagnosed T2DM first recognized during pregnancy by 
recommending screening for T2DM at booking visit [63,64]   
Following the diagnosis of GDM or pre-GDM, normalization of maternal blood 
glucose by using nutritional regiments and if needed insulin, is of paramount 
importance to prevent the complications of GDM and pre-GDM [16]. Based on the 
Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) and the 
blood glucose level of non-diabetic pregnant women, the recommendation for the 
target blood glucose levels during pregnancy are; FBG < 5.3 mmo/l, 1hour post-meal 
< 7.8 mmol/l and 2hours post-meal < 6.7 mmol/l. Close monitoring of maternal blood 
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glucose by daily testing of fasting and postprandial levels with monitoring of long 
term control by HbA1c levels, provide valuable information for adjustment of insulin 
therapy [65].   
Dietary advice and exercise were found to be effective in the prevention of GDM. 
However, the quality of evidence was low as concluded by a recent systematic review 
[66]. 
Management of labour and delivery in women with pre-GDM and GDM:   
One of the main concerns in the management of pregnant women with diabetes is the 
increased risk of stillbirth; [67]. The main etiology of stillbirth in diabetic pregnancy 
is chronic intra-uterine hypoxia secondary to placental vascular pathology [68]. In 
addition to close fetal surveillance, induction of labour (IOL) is offered to pregnant 
women with diabetes to avoid sudden intra-uterine fetal death. Moreover IOL for 
pregnant diabetic women at 38 gestation weeks was proven to improve other 
outcomes such as fetal macrosomia and shoulder dystocia without increasing the risk 
of C/S delivery [69,70]. Despite the frequent use of IOL for the management of 
pregnant women with diabetes there is paucity of evidence about the safety and 
determinants for successful IOL in Saudi Arabia.  
From the aforementioned summary of the problem of pre-GDM and GDM there were 
unanswered questions which have international and national impact on these 
condition and these were: 
1. No high grade evidence for the effectiveness of PCC. 
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2. No clear evidence for the safety of PCC with tight glycemic control. 
3. Investigation of the prevalence of pre-GDM and GDM in Saudi Arabia with 
preliminary studies which form the base for population based studies to 
evaluate all aspects of pre-GDM and GDM including health service provision.  
4. There is paucity of evidence about the determinants of success for a common 
intervention in the management of diabetic pregnant women which is IOL.    
Our first study was designed to investigate the effectiveness of PCC (publication 1). 
As tight glycemic control is associated with significant risk of hypoglycemia, we 
designed a second study to incorporate the safety element of the PCC (publication 2). 
To assess the scale of the problem of pre-GDM in KSA, a third study was designed to 
investigate the prevalence of pre-GDM and its effects on the pregnancy outcomes, in 
a real life setting (publication 3). Similarly, a separate study was conducted to 
investigate the prevalence of GDM and its effects (publication 4). Finally, induction 
of labour is a common mode of delivery intervention in both pre-GDM and GDM, 
however, real life data on the outcomes of induction of labour is not known in KSA. 
It is conceivable with increasing number of induction of labour, failure of induction 
can happen more often resulting in potentially more adverse perinatal outcomes 
including emergency C/S. Hence we designed an exploratory observational study to 
assess the indications of IOL and the factors associated with successful IOL 
(publication 5). 
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Published article 1[49] 
Preconception Care for Diabetic Women for Improving Maternal and Fetal 
Outcomes: a Systematic Review and Meta-analysis 
Introduction: 
Despite improved access and quality of antenatal care, women with pre-gestational 
diabetes and their fetuses are at increased risk of developing serious complications 
compared with the non-diabetic pregnant women, including spontaneous abortion, 
preterm labour, hypertensive disorders, congenital malformations, delivery by C/S 
and increased perinatal mortality rate [50,51]. In the recent report of The Confidential 
Inquiry into Maternal and Child Health (CEMACH) from England, Wales and 
Northern Ireland, the perinatal mortality for mothers with T1DM and T2DM was four 
times higher and the congenital malformations were twice as much as the background 
population [50]. Similar reports from North America showed no significant 
improvement in fetal and neonatal outcomes of women with pre-GDM between 1988 
and 2002 [71] despite the Saint Vincent Declaration in 1989 which sets a healthcare 
goal to improve the outcome of pregnancies in diabetic women [72]. Similar reports 
from the Middle East showed higher rate of perinatal mortality in diabetic as 
compared to non-diabetic women [73].  
Many of the complications of pre-GDM during pregnancy can be prevented by 
optimizing maternal health in the preconception period. Glycemic control is one of 
the most important aspects of PCC [56,57] ; however other aspects such as folic acid 
supplementation, smoking cessation, screening and treatment of diabetes 
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complications and discontinuing teratogenic medication, are as important for 
improving maternal and fetal outcomes [57].   
We carried out this systematic review to assess the effectiveness and safety of PCC in 
improving maternal and fetal outcomes for women with T1DM and T2DM and to 
provide high level of evidence to guide practice and policy in the management of 
women with pre-GDM.  
Methods:  
We searched the following databases, MEDLINE, EMBASE, WEB OF SCIENCE, 
Cochrane Library, including the CENTRAL register of controlled trials and CINHAL 
up to December 2009, without language restriction, for any preconception care 
aiming at health promotion, glycemic control and screening and treatment of diabetes 
complications in women of reproductive age group with type I or type II diabetes. 
Study design were trials (randomized and non-randomized), cohort and case-control 
studies. Of the 1612 title scanned 44 full papers were retrieved of those 24 were 
included in this review. Twelve cohort studies at low and medium risk of bias, with 
2502 women, were included in the meta-analysis. 
Results: 
Meta-analysis suggested that preconception care is effective in reducing congenital 
malformation, RR 0.25 (95% CI 0.15-0.42), NNT17 (95% CI 14-24), preterm 
delivery, RR 0.70 (95% CI 0.55-0.90), NNT= 8 (95% CI 5-23) and perinatal 
mortality RR 0.35 (95% CI 0.15-0.82), NNT= 32 (95% CI 19-109). Preconception 
care lowers HbA1c in the first trimester of pregnancy by an average of 2.43% (95% 
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CI 2.27-2.58). Women who received preconception care booked earlier for antenatal 
care by an average of 1.32 weeks (95% CI 1.23-1.40). 
The effectiveness of preconception care in improving maternal and fetal 
outcomes  
Figure (1): Risk ratio for congenital malformations from 11 studies of women 
with preexisting diabetes mellitus who did or did not receive preconception 
care.  
 
PCC= the group who received preconception care; NPCC= the group who did not 
received preconception care; CI= Confidence intervals. 
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Figure (2): Risk ratio for preterm delivery from 4 studies of women with 
preexisting diabetes mellitus who did or did not receive preconception care. 
 
PCC= Preconception care; NPCC= No preconception care; CI= Confidence intervals. 
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Figure (3): Risk ratio for perinatal mortality from 5 studies of women with 
preexisting diabetes mellitus who did or did not receive preconception care.  
PCC= the group who received preconception care; NPCC= the group who did not 
received preconception care; CI= Confidence intervals. 
Summary and significance of publication 1: 
This systematic review provided high level evidence for the effectiveness of PCC in 
improving many of the maternal and neonatal complications associated with pre-
GDM. It is the first systematic review addressing the effectiveness of PCC since the 
last systematic review was published by Ray et al in 2001[56].  
PCC reduced congenital malformations by 75%. This remarkable reduction in the 
prevalence of congenital malformations has practical implications for many 
communities worldwide, where congenital malformations due to diabetes and other 
causes, constitute a major health problem [50,74,75].  
The meta-analysis from this systematic review proved that women who attended PCC 
had 30% reduction in the rate of preterm delivery compared to women who did not. 
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The effect of PCC in reducing the rate of congenital malformations and preterm 
deliveries reflected positively on its effect in reducing the perinatal mortality among 
women who utilized the care with reduction of 65% in perinatal mortality rate 
compared to women who did not attend PCC. A population based study showed that; 
in women with pre-GDM, 16-28% of perinatal mortality is due to congenital 
malformations, and an additional 21-41% is due to preterm delivery [76,77]. Since 
the rate of both complications improves with PCC, such major reduction in perinatal 
mortality is expected in women attending PCC.  
The strength of this review comes from the comprehensive evaluation of the available 
evidence on the effectiveness and safety of PCC together with the assessment of wide 
range of interventions which we considered as PCC and all the possible maternal, 
fetal and neonatal outcomes which are affected by maternal pre-GDM. We are aware 
of the limitations of the observational studies as the main source of evidence and the 
inherent bias associated with the design; however, randomized controlled trials to 
assess the effectiveness of PCC are neither ethical nor feasible. Nevertheless the 
nature of the intervention lent strength to the observational studies by avoiding certain 
biases known to occur in such study designs. Lack of allocation concealment and 
blinding of participants were avoided by recruiting the intervention and the control 
groups at different times during the course of the study (preconception period and 
antenatal period). Additionally, and due to the relatively short duration of the 
pregnancy, attrition bias was minimized.  
The review carries important implications for practice and research as it highlights the 
importance of the integration of PCC in the routine care of diabetic women during 
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their reproductive age, and have practical implication considering the many reports 
worldwide which showed that women with pre-GDM have worse pregnancy 
outcomes compared to non-diabetic women despite improved access and utilization 
of antenatal and intra-partum care [50]. One of the main obstacles to the full 
implementation of PCC programs is the failure of the target population to utilize the 
provided services [58]. We suggest that more research is needed in methods of 
encouraging diabetic women to utilize PCC. 
This systematic review was cited by 45 articles, books and documents including a 
World Health Organization’s document on the prevention of non-communicable 
diseases and promotion of maternal health [78]. In addition the review was the main 
evidence for the recommendation for implementation of PCC in the management of 
women with pre-GDM in international guidelines; Canadian Diabetes Association 
2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in 
Canada [79]. The review was included in Database of Abstract of Reviews of 
Effectiveness (DARE) as it meets the quality criteria set by York Center for Review 
and Dissemination.   
 
 
 
 
 
2014 Page 28 
 
Published article 2 [80] 
Pre-pregnancy care for women with pre-gestational diabetes mellitus: a 
systematic review and meta-analysis 
Introduction: 
Following the publication of additional articles on PCC [58,81] [82] [83] we felt the 
need to update our published systematic review to incorporate new evidence about 
safety of PCC thus we designed a second systematic review which resulted in this 
publication.   
Methods:  
We searched the following databases, MEDLINE, EMBASE, WEB OF SCIENCE, 
Cochrane Library, including the CENTRAL register of controlled trials and CINHAL 
up to December 2011, without language restriction, for any preconception care 
aiming at health promotion, glycemic control and screening and treatment of diabetes 
complications in women with type I or type II diabetes. Study design were trials 
(randomized and non-randomized), cohort and case-control studies.  
Results: 
Of the 2452 title scanned 54 full papers were retrieved of those 21 studies were 
included in this review. Twelve cohort studies at low and medium risk of bias, with 
3088 women, were included in the meta-analysis. Meta-analysis suggested that 
preconception care is effective in reducing congenital malformation, RR 0.25 (95% 
CI 0.16-0.37), NNT19 (95% CI 14-24), and perinatal mortality RR 0.34 (95% CI 
0.15-0.75), NNT= 46 (95% CI 28-115). Preconception care lowers HbA1c in the first 
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trimester of pregnancy by an average of 1.92% (95% CI -2.05 to -1.79). However 
women who received preconception care were at increased risk of hypoglycemia 
during the first trimester of pregnancy RR 1.51 (95% CI 1.15-1.99). 
The effectiveness and safety of preconception care in improving maternal and 
fetal outcomes  
Figure (4): First trimester mean value of glycosylated hemoglobin A1C from five 
studies of women with pre-gestational diabetes mellitus who did or did not 
receive pre-pregnancy care.   
 
PPC (experimental) = the group who received pre-pregnancy care; NPPC 
(control) = the group who did not received pre-pregnancy care; CI = Confidence 
intervals. 
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Figure (5): Risk ratio of maternal hypoglycemia from two studies of women with 
preexisting diabetes mellitus who did or did not receive preconception care.    
 
PCC= the group who received preconception care; NPCC= the group who did not 
received preconception care; CI= Confidence intervals.  
Summary and significance of publication 2: 
This publication confirmed the findings of the first systematic review on the 
effectiveness of PCC on reducing the rate of congenital malformations, perinatal 
mortality, and the level of hemoglobin A1C in the first trimester of pregnancy in 
diabetic women who utilized PCC compared to those who did not. It also confirmed 
the previous findings of early utilization of antenatal care by women who had PCC 
compared to those who did not by nearly two weeks. However this systematic review 
provided stronger evidence due to the inclusion of 900 women more over the 
previous review in the meta-analysis in addition to the detailed explanation of the 
statistical heterogeneity noted in the meta-analysis of the effect of PCC on reducing 
hemoglobin A1C in the first trimester with the conclusion that the heterogeneity was 
in the magnitude of the reduction in hemoglobin A1C rather than in the direction of 
its effect. The other important heterogeneity was that associated with the occurrence 
of more attacks of severe hypoglycemia in women who utilized PCC compared to 
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women who did not. This statistical heterogeneity was explained by the variable 
effect size of PCC on maternal hypoglycemia in the two studies included in the meta-
analysis (see figure above). And this variable effect is due to the 16 year interval 
between the two studies and the many innovations in the treatment of diabetes in 
pregnancy such as patients’ education and counseling, intensive self-monitoring of 
blood glucose and functional insulin therapy. The conclusion from the analysis was 
that although meta-analysis suggested an increased risk of severe hypoglycemia with 
PCC, we believe this is an unlikely adverse effect with modern treatment and 
monitoring of diabetes during pregnancy. 
During the year and a half since this review was published it was cited by 7 articles 
and has been included in the DARE as it meets the quality criteria set by York Center 
for Review and Dissemination.   
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Published article 3 [26] 
Pre-existing diabetes mellitus and adverse pregnancy outcomes 
Introduction:  
Following the publication of our first systematic review and as part of our mission of 
transferring evidence into practice, we designed a strategy for knowledge translation 
of PCC to be integrated into the health services provision in KSA taking KKUH as a 
practical example. As the first step of the knowledge to action framework proposed 
by Graham et al is identification of the problem  [84], we needed information about 
the prevalence of pre-GDM among the pregnant population and its effects on the 
pregnancy outcomes.  
Since there is no national database for maternal diseases in KSA and the few 
published hospital based studies were more than a decade old, there was paucity of 
information about the prevalence of pre-GDM and its effects on the outcomes of 
pregnancy especially that the prevalence of T2DM has risen dramatically in the Saudi 
community, we designed this study to provide the necessary evidence to evaluate the 
problem of pre-GDM and its effect in the pregnancy outcome in the hospital.  
Methods: 
This was a retrospective cohort study for women who delivered in KKUH during the 
period of January 1st to the 31st of December 2008. The pregnancy outcomes of the 
women with pre-GDM were compared to the outcomes of all non-diabetic women 
who delivered during the same study period. Data compared included; age, parity, 
mode of delivery, premature delivery at less than 37 weeks of gestation, previous 
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history of miscarriage, birth weight, macrosomia, rate of APGAR scores less than 7 at 
five minutes and rate of stillbirth. Student t test was used to compare continuous 
variables and Chi square was used to compare categorical variables. Outcomes for 
macrosomia and mode of delivery were adjusted for maternal age and parity using 
regression analysis. 
Results: 
A total of 3157 deliveries met the inclusion criteria. Out of the study population 116 
(3.7%) women had pre-GDM. There were 66 (57%) women with T1DM and 50 
(43%) women with T2DM. Compared to non-diabetic women those with pre-GDM 
were significantly older, of higher parity and they had more previous miscarriages. 
Women with pre-GDM were more likely to be delivered by emergency C/S, OR 2.67, 
95% confidence intervals (CI) (1.63-4.32), p < 0.001, or elective C/S, OR 6.73, 95% 
CI (3.99-11.31), p < 0.001. The neonates of the mothers with pre-GDM were 
significantly heavier, p < 0.001; and more frequently macrosomic; OR 3.97, 95% CI 
(2.03-7.65), p 0.002. They more frequently have APGAR scores <7 in 5 minutes, OR 
2.61, 95% CI (0.89-7.05), p 0.057 and more likely to be delivered at <37 gestation 
weeks, OR 2.24, 95% CI (1.37- 3.67), p 0.003. The stillbirth rate was 2.6 times more 
among the women with pre-GDM; however the difference did not reach statistical 
significance, p 0.084. 
Summary and significance of publication 3: 
The results of this study were pivotal for further planning for implementation of PCC. 
The prevalence of pre-GDM in this study was 3.7% which indicates a fivefold 
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increase during the last 14 years based on earlier studies from Saudi Arabia [39,85].  
The results proved that almost 4 of every 100 women who deliver in the hospital has 
pre-GDM in addition to 18 women who develop GDM during the course of their 
pregnancy with the result that almost 25% of the women who deliver in the hospital 
are at increased risk of adverse maternal and perinatal outcomes. Moreover the study 
showed that 50% of women with pre-GDM were delivered by C/S compared to less 
than 20% C/S rate among non-diabetics. While only 3% of infants of non-diabetic 
mothers were macrosomic, 11% of infants of diabetic mothers were macrosomic. The 
study proved that diabetic mothers were at increased risk of preterm delivery and 
delivery of stillbirth.  
Because early screening of pregnant women for pre-GDM during the first trimester of 
pregnancy was not in the antenatal care protocol of the maternity unit in KKUH, it is 
plausible to assume that a proportion of women, who were diagnosed with GDM, 
later in pregnancy during screening, had undiagnosed T2DM. These results reflect 
both a major clinical and public health problem considering the high prevalence of 
diabetes in pregnancy in this sample.  
The results of this study were communicated to the head of the department of 
obstetrics and gynecology at KKUH in written form with the following 
recommendations: 
1. Because of the documented high prevalence of T2DM in the Saudi population 
we recommend that all pregnant women be screened early in pregnancy 
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(during the first trimester) using fasting blood glucose to identify women with 
pre-GDM. 
2. Close monitoring and adjustment of insulin therapy based on daily self-
monitoring of blood glucose with clear target of blood glucose level values for 
fasting and postprandial and periodically assessed hemoglobin A1C levels, is 
imperative for improving the outcomes for women with pre-GDM. 
3. The integration of PCC in the health service provision for women in the 
reproductive age with pre-GDM.  
In addition the results of this study were presented during a one-day seminar in 
knowledge translation for which officials from the Saudi Ministry of Health and 
members of obstetrics and gynecology departments in teaching and other 
governmental hospitals were invited. 
Since publication this article was cited by 9 other articles.  
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Published article 4 [27]  
Gestational diabetes mellitus: maternal and perinatal outcomes in King Khalid 
University Hospital, Saudi Arabia 
Introduction: 
Based on the results of the aforementioned study about the pre-existing diabetes and 
pregnancy outcomes, and due to the high prevalence of GDM detected in that study 
compared to previous studies from KSA [39], this study was designed to provide 
updated data about the prevalence of GDM and the outcomes of pregnancies in 
women who develop GDM in KKUH.  
Methods: 
This is a retrospective cohort study investigating the maternal and the neonatal 
outcomes of women with GDM who delivered in KKUH as compared with the 
outcomes of non-diabetic women who delivered during the same period. The data 
were collected from the 1st of January to the 31st of December 2010 from the labour 
ward registry. The pregnancy outcomes of the women with GDM were compared 
with the outcomes of non-diabetic women who delivered during the same study 
period. Data compared included; age, parity, mode of delivery, premature delivery at 
less than 37 weeks of gestation, birth weight, macrosomia, rate of APGAR scores less 
than 7 at 5 minutes and rate of stillbirth. Data were analyzed using the statistical 
package for the social sciences, version 17 (SPSS Inc., Chicago, Illinois, USA). 
Means were compared using the Student t-test or one-way analysis of variance, as 
appropriate, and categorical variables were compared using Chi square or Fisher 
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exact test, as appropriate. P value and odds ratio (OR) were calculated to test for 
significant differences between the groups. Outcomes for macrosomia and mode of 
delivery were adjusted for maternal age and parity using regression analysis. 
Differences at P < 0.05 were considered significant.  
Results: 
Out of 3041 women who delivered during the study period, 569 (18.7%) had GDM 
and 2472 (81.3%) were not diabetic. Compared with the non-diabetic women, women 
with GDM were more likely to be delivered by emergency C/S, odds ratio (OR) 1.30, 
95% confidence intervals (CI) (1.02–1.66), or elective C/S (OR 1.72, 95% CI 1.22–
2.44, p<0.001). The neonates of the mothers with GDM were significantly heavier 
and more frequently macrosomic (OR 1.75, 95% CI, 1.14–2.71, p<0.001). There was 
no significant difference between the two groups in the frequency of APGAR scores 
less than 7 in 5 min, preterm delivery at less than 37 weeks of gestation, or in the 
frequency of intrauterine fetal death. 
Summary and significance of publication 4: 
This study confirmed our previous findings of the high prevalence of nearly 19% of 
GDM in the studied population. This prevalence is among the highest reported in the 
region and world [10,17]. Moreover the results confirmed that women with GDM 
were disadvantaged by worse pregnancy outcomes compared to the non-diabetic 
women; including a significantly higher rate of C/S delivery and a higher rate of 
macrosomia. The results of this study gave indications to the inclusion of women with 
undiagnosed T2DM in the cohort, such as the increased frequency of previous 
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miscarriage in the women with GDM compared to the non-diabetic women. However 
the pregnancy outcomes of women with GDM were better compared to the women 
with pre-GDM from the previous study evident by similar prevalence of preterm 
delivery and stillbirth to that of the non-diabetic women.  
Table (1): The maternal and neonatal outcomes of women with gestational 
diabetes mellitus and non-diabetic women. 
 
Characteristic  
 
Non-diabetic   
 
 
2472 (81.3%) 
 
Gestational  
Diabetes Mellitus  
 
569 (18.7%) 
 
OR (95%CI) 
 
P value  
 
Emergency C/S 
 
340 (13.8%) 
 
98 (17.3%) 
 
1.37 (1.07-1.76) 
 
 
< 0.001 
 
Elective C/S 
 
125 (5.1%) 
 
48(8.5%) 
 
1.83 (1.29-2.59) 
 
 
< 0.001 
 
APGAR scores 
at 5 minutes <7 
42 (1.7%) 
 
6 (1.1%) 
 
0.62 (0.26-1.46) 
 
 
0.269 
 
Birth weight 
 
3120.14 ±578.18 
 
3197.60 ± 556.67 
  
< 0.001 
 
Macrsomia 
 
76 (3.1%) 
 
30 (5.3%)  
 
1.76 (1.14- 2.71) 
 
 
0.010 
 
IUFD 
 
32 (1.3%) 
 
5 (0.9%)  
 
0.68 (0.26-1.75) 
 
 
0.419 
 
Delivery < 37 
weeks 
 
222 (9%) 
 
48 (8.5%)  
 
0.94 (0.68- 1.29) 
 
 
0.696 
 
OR= Odds Ratio, CI= Confidence intervals, C/S= Cesarean section, IUFD= Intra-
uterine fetal death,  
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The results of this study were communicated to the head of the department of 
obstetrics and gynecology at KKUH in written form with the following 
recommendations: 
1. The results of this study suggested a high prevalence of GDM among the 
women attending KKUH for antenatal care and delivery, hence we suggest a 
policy of universal screening rather than risk factor based screening for GDM. 
2. Early screening of pregnant women, during the first trimester, for undiagnosed 
T2DM will facilitate early detection and control and hence better outcome for 
this category of pregnant women.  
3. The obstetrics and gynecology department in the University Hospital should 
take the lead for development of national guidelines for the management of 
GDM in KSA in light of the recent evidence. 
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Published article 5 [86]: 
Factors associated with successful induction of labour 
Introduction: 
Following the evaluation of the screening protocols for pre-GDM and GDM in the 
hospital and the outcomes of pregnancies complicated with maternal diabetes, in 
publications 3 and 4, we designed this study to evaluate an important clinical 
intervention commonly offered to pregnant women with pre-GDM and GDM which 
is IOL.  
Induction of labour is iatrogenic termination of pregnancy before the onset of 
spontaneous labour. It is frequently used to avoid serious complications to the mother 
or the fetus, arising from conditions such as; pre-eclampsia, maternal diabetes, 
intrauterine growth restriction and post-term pregnancy. Nevertheless, IOL may result 
in undesirable effects, such as increased rate of C/S, post-partum hemorrhage and 
fetal distress; therefore, it should only be considered when the benefits to the mother 
and her fetus outweigh the risks of waiting for spontaneous onset of labour. 
One of the main concerns in the management of pregnant women with diabetes is the 
increased risk of stillbirth; this was demonstrated by our third publication where the 
stillbirth rate in diabetic mothers was more than twofold higher in mothers with 
diabetes than the non-diabetic. This result is consistent with the findings of other 
reviewers [67]. The main etiology of stillbirth in diabetic pregnancy is thought to be 
chronic intra-uterine hypoxia. This was evident by the increased level of amniotic 
fluid erythropoietin and the depleted iron store in the fetal liver as a result of 
increased production of fetal hemoglobin to face the increased need for oxygen [68]. 
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In addition to close fetal surveillance, IOL is offered to pregnant women with 
diabetes to avoid sudden intrauterine fetal death. Moreover IOL for pregnant diabetic 
women at 38 gestation weeks was proven to improve other outcomes such as fetal 
macrosomia and shoulder dystocia without increasing the risk of C/S delivery [69,70] 
Methods:  
This study is a hospital based prospective cohort study of obstetric patients booked 
for IOL at the Obstetrics and Gynecology Department at KKUH, from April 2010 to 
March 2011. All women booked for IOL during the study period were included. 
Successful IOL was defined as achieving vaginal delivery. To assess the general 
characteristics of the women and their pregnancies as predictors of outcome of IOL, 
data from women who had successful IOL were compared to the women who were 
delivered by C/S, these characteristics included; maternal age, body mass index 
(BMI), parity, gestation age at IOL, indication for IOL, method of IOL, Bishop score 
at the commencement of IOL and birth weight. Other outcomes investigated included 
APGAR score at one and five minutes after delivery. The characteristics of women 
who had successful IOL were compared to those who delivered by C/S. To assess 
complication rate associated with IOL, we compared the prevalence of postpartum 
hemorrhage and ruptured uterus between the women who had IOL and women who 
had spontaneous labour. Data were analyzed using the Statistical Package for Social 
Sciences version 17 (SPSS Inc., Chicago, IL, USA). Means were compared using the 
Student t-test and Chi square test was used to compare categorical variables. A 
p<0.05 was considered significant. Crude odds ratio (OR) and their respective 95% 
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confidence intervals (95% CI) were estimated, adjusted ORs were calculated using 
multiple logistic regression models. 
Results:  
The total number of deliveries during the study period was 3522, of which 564 
underwent IOL. The prevalence of IOL was 16%. Vaginal delivery was achieved in 
472 (84%) women. The most common indications for IOL were post-term pregnancy 
in 174 (31%), and diabetes mellitus in 131 (23.2%) of the participants. Maternal 
characteristics associated with risk of C/S were; nulliparity, odds ratio (OR) 1.58; 
95% confidence interval (CI) 1.09-2.320; p=0.01, and high maternal BMI (p=0.01). 
Neonates of women with successful IOL had significantly higher APGAR scores 
(p=0.04), and more frequent pH ≥7.1 at delivery (p=0.02). There was no difference in 
the rate of post-partum hemorrhage, C/S, or ruptured uterus between the women who 
had IOL and those who went into spontaneous labour. 
Summary and significance of publication 5: 
This study was the first to investigate the intervention of IOL in KSA. The study 
proved that, in KKUH, diabetes in pregnancy is one of the main indications for IOL, 
which reflects the high prevalence of pre-GDM and GDM in the studied population. 
However despite the large number of diabetic women in this cohort, the rate of IOL 
of 16% is relatively low compared to that of the West of 33% [87,88]. This can be 
explained by the policy of the obstetric department which restricts IOL to medical 
indications and excludes elective IOL from its protocol.  
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The high success rate of IOL of 84% is comparable to that reported by others who 
reported similar policy of using cervical ripening before IOL [88]. 
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Table 2 Maternal and Fetal Characteristics associated with successful induction 
of labour 
 
 
Characteristics 
 
 
Women who 
had  vaginal 
delivery 
 
472 (84%) 
 
       No (%)* 
 
 
Women who 
delivered by 
cesarean 
section 
92 (16%) 
 
        No (%)* 
 
 
OR (95% CI) 
 
 
P value 
 
Maternal age  
≤ 35 years 
 
 
 
328 (74.4) 
 
 
 
62 (72.9)                
 
 
 
1.07 (0.64-1.8) 
   
 
0.78 
 
Nullipara  
 
 
183 (38.6) 
 
 
47 (52.2) 
 
 
1.58 (1.09-2.32) 
 
0.01 
 
Gestation age 
(week)  37+  
 
384 (83.5) 
 
68 (79.1) 
 
0.79 (0.49-1.25) 
 
0.32 
 
 
Post term 
 > 41 weeks 
 
140 (30.4) 
 
31(36.0)                  
 
1.25(0.78-2.02) 
 
0.35 
 
 
Maternal diabetes 
as indication for 
IOL 
 
 
 
114 (24.1) 
 
 
 
17 (18.9) 
 
 
 
0.735(0.41-1.29) 
 
 
 
0.28 
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BMI  (kg ⁄m2) 
( mean ± SD) 
 
32.56 ± 6.09 34.22 ± 6.05 0.01 
 
Bishop score 
 < 5 
  
 
325 (68.7)                
 
 
67 (74.4) 
 
 
1.32 (0.79-2.21) 
 
0.31 
 
Cervical dilatation  
<2 cm 
 
349 (75.2) 
 
72 (80.9) 
 
1.39 (0.79-2.47) 
 
0.25 
 
 
Birth weight  
<2500g 
 
 
57 (12.2) 
 
 
17 (18.9) 
  
 
1.68 (0.88-3.15) 
 
0.09 
Birth weight 
≥4000g 
 
 
24 (5.1) 
 
7 (7.8) 
 
1.55 (0.59-3.95) 
 
 
0.33 
BMI= Body mass index 
*The difference in percentages is due to missing data 
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Figure (6): Indications for induction of labour 
 
GDM=Gestational diabetes, DM=Diabetes Mellitus, ROM=Rupture of Membranes, 
IUGR=Intra-uterine growth restriction, Fetal com= Fetal compromise, PIH= 
Pregnancy induced hypertension, MMC= Maternal Medical Condition, IUFD = 
Intrauterine Fetal Death, ISO immunization= Rhesus iso-immunization, APH= Ante-
partum hemorrhage, IOL = Induction of labour  
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Future directions and implications of the publications: 
Preconception or in-between pregnancy care is a contemporary shift in the paradigm 
of management of women in the reproductive age.  The importance of planning 
pregnancy and implementing interventions to prevent detrimental effects of pre-
existing maternal conditions and behaviors, such as obesity, smoking and 
uncontrolled hyperglycemia of T1DM and T2DM, on the pregnancy outcomes is no 
longer disputed [49,89,90]. However it is increasingly recognized that utilization of 
such care by women is hindered by the high number of unplanned pregnancies and 
other psychosocial factors [91]. As we recommended in our reports of the systematic 
reviews, the future direction for PCC, should focus on investigating the barriers for 
utilization and the incorporation of PCC into the daily health services of women with 
chronic health conditions such as DM.   
Our studies on pre-GDM and GDM had major impact on the practice in the obstetric 
department of KKUH; mainly through implementation of new clinical practice 
guidelines based on the recommendation of the IADPSG and universal screening for 
pre-GDM and GDM.  
Based on the results of our studies which demonstrated that mothers with pre-GDM 
and GDM are at increased risk of adverse pregnancy outcomes and our awareness of 
the lack of national database for pregnancy complications; we planned and started a 
multicenter cohort study under the title Riyadh Birth Cohort (RBC). This study is 
expected to provide data pivotal for maternal health policy planning in addition to the 
opportunity to conduct many longitudinal studies on the mothers and their offspring.     
2014 Page 48 
 
Reference List 
 
 1.  Wild  S, Roglic  G, Green  A, Sicree  R, King  H: Global prevalence of 
diabetes: estimates for the year 2000 and projections for 2030. Diabetes 
Care 2004, 27: 1047-1053. 
 2.  Al-Nuaim  AR: Prevalence of glucose intolerance in urban and rural 
communities of Saudi Arabia. Diabetic Medicine 1997, 14: 595-602. 
 3.  Hotu  S, Carter  B, Watson  PD, Cutfield  WS, Cundy  T: Increasing 
prevalence of type 2 diabetes in adolescents . journal of paediatric and 
child health 2004, 40: 201-204. 
 4.  Lapolla A, Dalfra MG, Di CG, Bonomo M, Parretti E, Mello G: A 
multicenter Italian study on pregnancy outcome in women with diabetes. 
Nutr Metab Cardiovasc Dis 2008, 18: 291-297. 
 5.  Macintosh MC, Fleming KM, Bailey JA, Doyle P, Modder J, Acolet D et al.: 
Perinatal mortality and congenital anomalies in babies of women with 
type 1 or type 2 diabetes in England, Wales, and Northern Ireland: 
population based study. BMJ 2006, 333: 177. 
 6.  Balsells M, Garcia-Patterson A, Gich I, Corcoy R: Maternal and fetal 
outcome in women with type 2 versus type 1 diabetes mellitus: a 
systematic review and metaanalysis. J Clin Endocrinol Metab 2009, 94: 
4284-4291. 
 7.  Verheijen EC, Critchley JA, Whitelaw DC, Tuffnell DJ: Outcomes of 
pregnancies in women with pre-existing type 1 or type 2 diabetes, in an 
ethnically mixed population. BJOG 2005, 112: 1500-1503. 
 8.  Chaudhry T, Ghani AM, Mehrali TH, Taylor RS, Brydon PA, Gee H et al.: A 
comparison of foetal and labour outcomes in Caucasian and Afro-
Caribbean women with diabetes in pregnancy. Int J Clin Pract 2004, 58: 
932-936. 
 9.  American Diabetes Association: Diagnosis and classification of diabetes 
mellitus. Diabetes Care 2006, S43-8. 
 10.  Hunt KJ, Schuller KL: The increasing prevalence of diabetes in pregnancy. 
Obstet Gynecol Clin North Am 2007, 34: 173-99, vii. 
 11.  Ben-Haroush A, Yogev Y, Hod M: Epidemiology of gestational diabetes 
mellitus and its association with Type 2 diabetes. Diabet Med 2004, 21: 
103-113. 
2014 Page 49 
 
 12.  Jang HC: Gestational diabetes in Korea: incidence and risk factors of 
diabetes in women with previous gestational diabetes. Diabetes Metab J 
2011, 35: 1-7. 
 13.  Albareda M, Caballero A, Badell G, Piquer S, Ortiz A, de LA et al.: Diabetes 
and abnormal glucose tolerance in women with previous gestational 
diabetes. Diabetes Care 2003, 26: 1199-1205. 
 14.  Anna V, van der Ploeg HP, Cheung NW, Huxley RR, Bauman AE: 
Sociodemographic correlates of the increasing trend in prevalence of 
gestational diabetes mellitus in a large population of women between 1995 
and 2005. Diabetes Care 2008, 31: 2288-2293. 
 15.  Alshami HA, Kadasne AR, Khalfan M, Iqbal SZ, Mirghani HM: Pregnancy 
outcome in late maternal age in a high-income developing country. Arch 
Gynecol Obstet 2010. 
 16.  Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS: 
Effect of treatment of gestational diabetes mellitus on pregnancy 
outcomes. N Engl J Med 2005, 352: 2477-2486. 
 17.  Barakat MN, Youssef RM, Al-Lawati JA: Pregnancy outcomes of diabetic 
women: charting Oman's progress towards the goals of the Saint Vincent 
Declaration. Ann Saudi Med 2010, 30: 265-270. 
 18.  Metzger BE: Long-term outcomes in mothers diagnosed with gestational 
diabetes mellitus and their offspring. Clin Obstet Gynecol 2007, 50: 972-
979. 
 19.  Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Yousef M, Sabico 
SL et al.: Diabetes mellitus type 2 and other chronic non-communicable 
diseases in the central region, Saudi Arabia (riyadh cohort 2): a decade of 
an epidemic. BMC Med 2011, 9: 76. 
 20.  Fatani HH, Mira SA, el-Zubier AG: Prevalence of diabetes mellitus in rural 
Saudi Arabia. Diabetes Care 1987, 10: 180-183. 
 21.  Majeed A, El-Sayed AA, Khoja T, Alshamsan R, Millett C, Rawaf S: 
Diabetes in the Middle-East and North Africa: An update for 2013 for the 
IDF Diabetes Atlas. Diabetes Res Clin Pract 2013. 
 22.  Khandekar R, Al LJ, Mohammed AJ, Al RA: Diabetic retinopathy in 
Oman: a hospital based study. Br J Ophthalmol 2003, 87: 1061-1064. 
 23.  Al-Rowaily MA, Abolfotouh MA: Predictors of gestational diabetes 
mellitus in a high-parity community in Saudi Arabia. East Mediterr Health 
J 2010, 16: 636-641. 
2014 Page 50 
 
 24.  El-Gilany AH, Hammad S: Body mass index and obstetric outcomes in 
pregnant in Saudi Arabia: a prospective cohort study. Ann Saudi Med 
2010, 30: 376-380. 
 25.  Meher UN: Impact of obesity on fetomaternal outcome in pregnant saudi 
females. Int J Health Sci (Qassim ) 2011, 5: 40-41. 
 26.  Wahabi HA, Esmaeil SA, Fayed A, Al-Shaikh G, Alzeidan RA: Pre-existing 
diabetes mellitus and adverse pregnancy outcomes. BMC Res Notes 2012, 
5: 496. 
 27.  Wahabi HA, Esmaeil SA, Fayed A, Alzeidan RA: Gestational diabetes 
mellitus: maternal and perinatal outcomes in King Khalid University 
Hospital, Saudi Arabia. J Egypt Public Health Assoc 2013, 88: 104-108. 
 28.  Abdalrahman AA: Maternal and neonatal outcome of controlled 
gestational diabetes mellitus versus high risk group without gestational 
diabetes mellitus: a comparative study. Med Glas (Zenica ) 2013, 10: 70-
74. 
 29.  Alsammani MA, Ahmed SR: Fetal and maternal outcomes in pregnancies 
complicated with fetal macrosomia. N Am J Med Sci 2012, 4: 283-286. 
 30.  Al-Khalifah R, Al-Subaihin A, Al-Kharfi T, Al-Alaiyan S, Alfaleh KM: 
Neonatal short-term outcomes of gestational diabetes mellitus in saudi 
mothers: a retrospective cohort study. J Clin Neonatol 2012, 1: 29-33. 
 31.  Ryan EA, Enns L: Role of gestational hormones in the induction of insulin 
resistance. J Clin Endocrinol Metab 1988, 67: 341-347. 
 32.  Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin 
secretory dysfunction and insulin resistance in the pathogenesis of type 2 
diabetes mellitus. J Clin Invest 1999, 104: 787-794. 
 33.  Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ 
et al.: Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989, 
1: 293-295. 
 34.  Bottazzo GF, Florin-Christensen A, Doniach D: Islet-cell antibodies in 
diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 
1974, 2: 1279-1283. 
 35.  Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto J: Genetic 
liability of type 1 diabetes and the onset age among 22,650 young Finnish 
twin pairs: a nationwide follow-up study. Diabetes 2003, 52: 1052-1055. 
 36.  Hober D, Sauter P: Pathogenesis of type 1 diabetes mellitus: interplay 
between enterovirus and host. Nat Rev Endocrinol 2010, 6: 279-289. 
2014 Page 51 
 
 37.  Metzger BE, Persson B, Lowe LP, Dyer AR, Cruickshank JK, 
Deerochanawong C et al.: Hyperglycemia and adverse pregnancy outcome 
study: neonatal glycemia. Pediatrics 2010, 126: e1545-e1552. 
 38.  Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR et 
al.: Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008, 
358: 1991-2002. 
 39.  El Mallah KO, Narchi H, Kulaylat NA, Shaban MS: Gestational and pre-
gestational diabetes: comparison of maternal and fetal characteristics and 
outcome. Int J Gynaecol Obstet 1997, 58: 203-209. 
 40.  Allen VM, Armson BA, Wilson RD, Allen VM, Blight C, Gagnon A et al.: 
Teratogenicity associated with pre-existing and gestational diabetes. J 
Obstet Gynaecol Can 2007, 29: 927-944. 
 41.  Rackham O, Paize F, Weindling AM: Cause of death in infants of women 
with pregestational diabetes mellitus and the relationship with glycemic 
control. Postgrad Med 2009, 121: 26-32. 
 42.  Ojule JD, Fiebai PO, Okongwu C: Perinatal outcome of macrosomic births 
in Port Harcourt. Niger J Med 2010, 19: 436-440. 
 43.  Kock K, Kock F, Klein K, Bancher-Todesca D, Helmer H: Diabetes mellitus 
and the risk of preterm birth with regard to the risk of spontaneous 
preterm birth. J Matern Fetal Neonatal Med 2010, 23: 1004-1008. 
 44.  Bental Y, Reichman B, Shiff Y, Weisbrod M, Boyko V, Lerner-Geva L et al.: 
Impact of Maternal Diabetes Mellitus on Mortality and Morbidity of 
Preterm Infants (24-33 Weeks' Gestation). Pediatrics 2011. 
 45.  Denguezli W, Hemdane S, Faleh R, Laajili H, Saidan Z, Haddad A et al.: 
Prevalence and risk factors of cesarean section in a population of 
Tunisian diabetic pregnant women. Tunis Med 2007, 85: 935-940. 
 46.  Conway DL, Langer O: Elective delivery of infants with macrosomia in 
diabetic women: reduced shoulder dystocia versus increased cesarean 
deliveries. Am J Obstet Gynecol 1998, 178: 922-925. 
 47.  Stuart AE, Matthiesen LS, Kallen KB: Association between 5 min Apgar 
scores and planned mode of delivery in diabetic pregnancies. Acta Obstet 
Gynecol Scand 2011, 90: 325-331. 
 48.  Rouse DJ, Owen J, Goldenberg RL, Cliver SP: The effectiveness and costs 
of elective cesarean delivery for fetal macrosomia diagnosed by 
ultrasound. JAMA 1996, 276: 1480-1486. 
2014 Page 52 
 
 49.  Wahabi HA, Alzeidan RA, Bawazeer GA, Alansari LA, Esmaeil SA: 
Preconception care for diabetic women for improving maternal and fetal 
outcomes: a systematic review and meta-analysis. BMC Pregnancy 
Childbirth 2010, 10: 63. 
 50.  Confidential Enquiry into Maternal and Child Health (CEMACH). 
Pregnancy in Women with type 1 and type 2 Diabbetes in 2002-
2003.England ,Wales and Northern Ireland. London. CEMACH 2005. 
 51.  Casson IF, Clarke CA, Howard CV, McKendrick O, Pennycook S, Pharonah 
PO et al.: Outcomes of pregnancy in insulin dependent diabetic 
women:result of a five year population cohort study. BMJ 1997, 315: 275-
278. 
 52.  Ray JG, Vermeulen MJ, Meier C, Wyatt PR: Risk of congenital anomalies 
detected during antenatal serum screening in women with pregestational 
diabetes. QJM 2004, 97: 651-653. 
 53.  Wren C, Birrell G, Hawthorne G: Cardiovascular malformations in infants 
of diabetic mothers. Heart 2003, 89: 1217-1220. 
 54.  Reece EA: Maternal fuels, diabetic embryopathy: pathomechanisms and 
prevention. Semin Reprod Endocrinol 1999, 17: 183-194. 
 55.  Mathiesen ER, Ringholm L, Damm P: Stillbirth in diabetic pregnancies. 
Best Pract Res Clin Obstet Gynaecol 2011, 25: 105-111. 
 56.  Ray JG, O'Brien TE, Chan WS: Preconception care and the risk of 
congenital anomalies in the offspring of women with diabetes mellitus: a 
meta-analysis. QJM 2001, 94: 435-444. 
 57.  Temple RC, Aldridge VJ, Murphy HR: Prepregnancy care and pregnancy 
outcomes in women with type 1 diabetes. Diabetes Care 2006, 29: 1744-
1749. 
 58.  Murphy HR, Roland JM, Skinner TC, Simmons D, Gurnell E, Morrish NJ et 
al.: Effectiveness of a regional prepregnancy care program in women 
with type 1 and type 2 diabetes: benefits beyond glycemic control. 
Diabetes Care 2010, 33: 2514-2520. 
 59.  Steel JM, Johnstone FD, Hepburn DA, Smith AF: Can prepregnancy care of 
diabetic women reduce the risk of abnormal babies? BMJ 1990, 301: 
1070-1074. 
 60.  Vidaeff AC, Yeomans ER, Ramin SM: Gestational diabetes: a field of 
controversy. Obstet Gynecol Surv 2003, 58: 759-769. 
2014 Page 53 
 
 61.  Ezimokhai M, Joseph A, Bradley-Watson P: Audit of pregnancies 
complicated by diabetes from one center five years apart with selective 
versus universal screening. Ann N Y Acad Sci 2006, 1084: 132-140. 
 62.  Hieronimus S, Le Meaux JP: Relevance of gestational diabetes mellitus 
screening and comparison of selective with universal strategies. Diabetes 
Metab 2010, 36: 575-586. 
 63.  Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P et 
al.: International association of diabetes and pregnancy study groups 
recommendations on the diagnosis and classification of hyperglycemia in 
pregnancy. Diabetes Care 2010, 33: 676-682. 
 64.  Nolan CJ: Controversies in gestational diabetes. Best Pract Res Clin Obstet 
Gynaecol 2011, 25: 37-49. 
 65.  de Valk HW, Visser GH: Insulin during pregnancy, labour and delivery. 
Best Pract Res Clin Obstet Gynaecol 2011, 25: 65-76. 
 66.  Oostdam N, van Poppel MN, Wouters MG, van MW: Interventions for 
Preventing Gestational Diabetes Mellitus: A Systematic Review and 
Meta-Analysis. J Womens Health (Larchmt ) 2011. 
 67.  Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A: Maternal and 
fetal risk factors for stillbirth: population based study. BMJ 2013, 346: 
f108. 
 68.  Teramo KA: Obstetric problems in diabetic pregnancy - The role of fetal 
hypoxia. Best Pract Res Clin Endocrinol Metab 2010, 24: 663-671. 
 69.  Kjos SL, Henry OA, Montoro M, Buchanan TA, Mestman JH: Insulin-
requiring diabetes in pregnancy: a randomized trial of active induction of 
labor and expectant management. Am J Obstet Gynecol 1993, 169: 611-
615. 
 70.  Rosenstein MG, Cheng YW, Snowden JM, Nicholson JM, Doss AE, Caughey 
AB: The risk of stillbirth and infant death stratified by gestational age in 
women with gestational diabetes. Am J Obstet Gynecol 2012, 206: 309-7. 
 71.  Yang J, Cummings EA, O'Connell C, Jangaard K: Fetal and Neonatal 
Outcomes of Diabetic Pregnancies. Obstetrics and Gynecology 2006, 108: 
644-650. 
 72.  Diabetes Care and Research in Europe. The Saint Vincent Declaration. 
Diabet Med 1990, 7. 
 73.  Sobande AA, Al-Bar H, Archibong E: Diabetes and Preinatal Loss. A 
continuing Problem. Saudi Med J 2000, 21: 161-163. 
2014 Page 54 
 
 74.  Hussain R, Bittles AH, Sullivan S: Consanguinity and early mortality in 
the Muslim populations of India and Pakistan. Am J Hum Biol 2001, 13: 
777-787. 
 75.  Al-Gazali L, Hamamy H, Al-Arrayad S: Genetic disorders in the Arab 
world. BMJ 2006, 333: 831-834. 
 76.  Jensen DM, Damm P, Moelsted-Pedersen L, Ovesen P, Westergaard JG, 
Moeller M et al.: Outcomes in type 1 diabetic pregnancies: a nationwide, 
population-based study. Diabetes Care 2004, 27: 2819-2823. 
 77.  Platt MJ, Stanisstreet M, Casson IF, Howard CV, Walkinshaw S, Pennycook 
S et al.: St Vincent's Declaration 10 years on: outcomes of diabetic 
pregnancies. Diabet Med 2002, 19: 216-220. 
 78.  World Health Organisation. Maternal and Child Health Knowledge Summary, 
Non-communicable Diseases.  2013.  
Ref Type: Online Source 
 79.  Canadian Diabetes Association Clinical Practice Guidelines Expert 
Committee:  Canadian Diabetes Association 2013 Clinical Practice 
Guidelines for the Prevention and Management of Diabetes in Canada . 
Can J Diabetes 2013, 37: S1-S212. 
 80.  Wahabi HA, Alzeidan RA, Esmaeil SA: Pre-pregnancy care for women 
with pre-gestational diabetes mellitus: a systematic review and meta-
analysis. BMC Public Health 2012, 12: 792. 
 81.  Tripathi A, Rankin J, Aarvold J, Chandler C, Bell R: Preconception 
counseling in women with diabetes: a population-based study in the north 
of England. Diabetes Care 2010, 33: 586-588. 
 82.  Shahidi S, Aghdak P, Farajzadegan Z, Izadi  M, Mohammadi M, Fard MN:  
Reviewing the effectiveness of pre-pregnancy counseling   protocol on 
pregnancy and labor indices. IJNMR 2011, 16. 
 83.  Anwar A, Salih A, Masson E, Allen B, Wilkinson L, Lindow SW: The effect 
of pre-pregnancy counselling for women with pre-gestational diabetes on 
maternal health status. Eur J Obstet Gynecol Reprod Biol 2011, 155: 137-
139. 
 84.  Graham ID, Logan J, Harrison MB, Straus SE, Tetroe J, Caswell W et al.: 
Lost in knowledge translation: time for a map? J Contin Educ Health Prof 
2006, 26: 13-24. 
 85.  Al Najashi SS, Al Umran KU: Congenital anomalies among infants of 
diabetic mothers: a study of 466 cases at King Fahd Hospital of the 
University, Al-Khobar. J Obstet Gynaecol 1997, 17: 23-25. 
2014 Page 55 
 
 86.  Al-Shaikh GK, Wahabi HA, Fayed AA, Esmaeil SA, Al-Malki GA: Factors 
associated with successful induction of labor. Saudi Med J 2012, 33: 298-
303. 
 87.  Humphrey T, Tucker JS: Rising rates of obstetric interventions: exploring 
the determinants of induction of labour. J Public Health (Oxf) 2009, 31: 
88-94. 
 88.  Laughon SK, Zhang J, Grewal J, Sundaram R, Beaver J, Reddy UM: 
Induction of labor in a contemporary obstetric cohort. Am J Obstet 
Gynecol 2012, 206: 486-489. 
 89.  Flower A, Shawe J, Stephenson J, Doyle P: Pregnancy planning, smoking 
behaviour during pregnancy, and neonatal outcome: UK Millennium 
Cohort Study. BMC Pregnancy Childbirth 2013, 13: 238. 
 90.  Hagberg LA, Brekke HK, Bertz F, Winkvist A: Cost-utility analysis of a 
randomized controlled weight loss trial among lactating overweight/obese 
women. BMC Public Health 2014, 14: 38. 
 91.  O'Higgins S, McGuire BE, Mustafa E, Dunne F: Barriers and facilitators to 
attending pre-pregnancy care services: the ATLANTIC-DIP experience. 
Diabet Med 2013. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2014 Page 56 
 
Appendix 1 
Publication list 
  
1. Wahabi HA, Alzeidan RA, Bawazeer GA, Alansari LA, Esmaeil SA. Preconception care for 
diabetic women for improving maternal and fetal outcomes: a systematic review and meta-
analysis.  BMC Pregnancy and Child birth 2010 Oct; 14 10:63 doi: 10.1186/1471-2393-10-
63. 
 
2. Wahabi HA, Alzeidan RA, Esmaeil SA. Pre-pregnancy care for women with pre-gestational 
diabetes mellitus: a systematic review and meta-analysis. BMC Public Health. 2012 Sep 17; 
12:792. doi: 10.1186/1471-2458-12-792. 
 
3. Wahabi HA, Esmaeil SA, Fayed A, Al-Shaikh G, Alzeidan RA. Pre-existing diabetes 
mellitus and adverse pregnancy outcomes. BMC Res Notes. 2012 Sep 10; 5:496. doi: 
10.1186/1756-0500-5-496. 
 
4. Wahabi HA, Esmaeil SA, Fayed A, Alzeidan RA. Gestational diabetes mellitus: maternal and 
perinatal outcomes in KKUH, Saudi Arabia. J Egypt Public Health Assoc. 2013 Aug; 88 
(2):104-8. doi: 10.1097/01.EPX.0000430392.57811.20. 
 
 
5. Al-Shaikh GK, Wahabi HA, Fayed AA, Esmaeil SA, Al-Malki GA. Factors associated with 
successful induction of labour. Saudi Med J. 2012 Mar; 33(3):298-303. 
 
 
  
